



The University of Vermont

OFFICE OF THE VICE PRESIDENT FOR RESEARCH

February 1, 2024

To Whom It May Concern:

This letter serves as confirmation that the University of Vermont has an A/BSL-3 high-containment facility designed for both *in vitro* and *in vivo* research requiring containment at BSL-3 and ABSL-3. The University has CDC approval to include work with certain Select Agents within this facility.

The facility is available to University of Vermont researchers who meet a minimum required experience threshold and have completed all required training, including site-specific procedures, and have obtained approval from the Institutional Biosafety Committee under the NIH Guidelines.

Sincerely,

Kirk Dombrowski
Vice President for Research & Economic Development